Jean-Pierre Sommadossi compensation by year
Atea Pharmaceuticals Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $400,000 | $436,862 | $650,000 | $650,000 | $683,000 | $703,490 | $703,490 |
| Bonus | $160,000 | $466,125 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $2,842,220 | $2,409,452 | $1,788,800 | $1,315,800 |
| Option awards | $251,080 | $1,984,000 | $33,123,392 | $1,937,306 | $2,474,763 | $1,372,358 | $962,368 |
| Non-equity incentive | $0 | $0 | $331,500 | $448,500 | $358,575 | $337,675 | $422,094 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total | $811,080 | $2,886,987 | $34,104,892 | $5,878,026 | $5,925,790 | $4,202,323 | $3,403,752 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Atea Pharmaceuticals, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182293, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Atea Pharmaceuticals, Inc. filed document, accession 0001193125-26-182293. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 430,000 | $1,535,100 | — |
| PSU | 215,000 | $767,550 | — |
| RSU | 173,466 | $619,274 | — |
| RSU | 99,517 | $355,274 | — |
| Option | 233,334 | — | $4.16 |
| Option | 197,330 | — | $4.63 |
| Option | 7,876 | — | $7.14 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Atea Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Atea Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jean-Pierre Sommadossi · this page | President, Chief Executive Officer and Chairman of the Board | $3,403,752 |
| Janet Hammond | Chief Development Officer | $1,767,234 |
| Andrea Corcoran | Chief Financial Officer, Executive Vice President, Legal | $1,690,428 |
| Maria Arantxa Horga | Chief Medical Officer | $1,593,827 |
| John Vavricka | Chief Commercial Officer | $1,217,738 |
Board service
Atea Pharmaceuticals board · FY2021–FY2025How this board is paid
Company policy: Atea Pharmaceuticals pays directors a $45,000 cash retainer. As stated in Atea Pharmaceuticals's FY2025 proxy.
The full Atea Pharmaceuticals compensation record
free company briefThis page is one person within Atea Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Atea Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Atea Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Atea Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order AVIR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.